Sugi Predict

Sugi Predict / Targets / CPN1

CPN1

Carboxypeptidase N catalytic chain · P15169 · CPN1 on Sugi Atlas →

4,589 patent compounds predicted against CPN1, 1,589 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2353967 SCHEMBL2353967 1.00 8/20
SCHEMBL2354438 SCHEMBL2354438 1.00 8/20
SCHEMBL2079843 SCHEMBL2079843 0.70 8/20
Piperidine Piperidine (SCHEMBL3443987) 0.59 7/20
SCHEMBL2349599 SCHEMBL2349599 1.00 6/20
SCHEMBL2352986 SCHEMBL2352986 1.00 6/20
SCHEMBL2353821 SCHEMBL2353821 1.00 6/20
SCHEMBL2354051 SCHEMBL2354051 1.00 6/20
SCHEMBL1775857 SCHEMBL1775857 0.67 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL910525) 0.65 6/20
SCHEMBL1206062 SCHEMBL1206062 0.50 6/20
SCHEMBL4978863 SCHEMBL4978863 0.41 6/20
SCHEMBL439640 SCHEMBL439640 0.40 6/20
SCHEMBL4008092 SCHEMBL4008092 0.59 5/20
SCHEMBL4008517 SCHEMBL4008517 0.57 5/20
SCHEMBL4635154 SCHEMBL4635154 0.43 5/20
Cyclohexane Cyclohexane (SCHEMBL253223) 0.42 5/20
SCHEMBL506450 SCHEMBL506450 0.42 5/20
SCHEMBL1199676 SCHEMBL1199676 0.42 5/20
Cyclohexane Cyclohexane (SCHEMBL4365734) 0.42 5/20

Clinical trials — most relevant to CPN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment PHASE4RECRUITING
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) PHASE3COMPLETED
Role of Antioxidants Supplementation in Chronic Pancreatitis PHASE3COMPLETED
A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis PHASE1/PHASE2COMPLETED
Stem Cell Gene Therapy for Cystinosis PHASE1/PHASE2COMPLETED
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract nanCOMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Multi-omics Study in Citrin Deficiency nanACTIVE_NOT_RECRUITING
Ovarian Reserve and Matrix Metalloproteinases nanCOMPLETED
Frequency of Pompe Disease in Patients With Myalgia With or Without Hyper Ckemia - Data From the Reference Center (CERCA) nanUNKNOWN
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
Proteomics of Primary Hyperoxaluria Type 1 nanCOMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Genetic Etiology in Patients With Cerebral Palsy nanCOMPLETED
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Longitudinal Study of the Porphyrias nanRECRUITING
Incidence of cCPHD in Denmark - a National Observational Study nanUNKNOWN
A Study of the Genetic Analysis of Brain Disorders nanCOMPLETED
Markers in Acute Pancreatitis-1 nanCOMPLETED
Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis nanCOMPLETED
CP-EDIT: Cerebral Palsy - Early Diagnosis and Intervention Trial nanRECRUITING
Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy nanCOMPLETED
The PORTRAIT Study nanUNKNOWN
Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin nanCOMPLETED
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis nanRECRUITING
Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CPN1 binder may also engage these)

ProteinNameSimilarity
Q9EQV8 — 1.000 Q9EQV8 →
Q9JJN5 — 1.000 Q9JJN5 →
Q2KJ83 — 0.997 Q2KJ83 →
Q00493 — 0.992 Q00493 →
P15087 — 0.991 P15087 →
P37892 — 0.989 P37892 →
P42787 — 0.988 P42787 →
Q96SM3 — 0.987 Q96SM3 →
Q80V42 — 0.987 Q80V42 →
A5A6K7 — 0.987 A5A6K7 →
P04836 — 0.987 P04836 →
P14384 — 0.985 P14384 →
P16870 — 0.985 P16870 →
O89001 — 0.985 O89001 →
Q5RFD6 — 0.984 Q5RFD6 →
Q9JHH6 — 0.984 Q9JHH6 →
Q66K79 — 0.984 Q66K79 →
Q8WXQ8 — 0.983 Q8WXQ8 →
O54858 — 0.982 O54858 →
Q8QGP3 — 0.982 Q8QGP3 →
Q28193 — 0.981 Q28193 →
Q9JHW1 — 0.981 Q9JHW1 →
Q9D2L5 — 0.981 Q9D2L5 →
Q8R4V4 — 0.981 Q8R4V4 →
Q4R4M3 — 0.980 Q4R4M3 →
CPA2 Carboxypeptidase A2 0.980 landscape →
A7ISW2 — 0.980 A7ISW2 →
Q0II73 — 0.980 Q0II73 →
O75976 — 0.979 O75976 →
Q9EQV9 — 0.979 Q9EQV9 →